Csl behring market cap
WebThe CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. ... MARKET … WebApr 6, 2024 · Market Cap. $96.53B. ... The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This ...
Csl behring market cap
Did you know?
WebCSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. ... Market Cap Shares Average Volume EPS; $202.01: $200.59: $167.67 - $222.32: $97.4B: 482M: 779K: $4.33: CSL Financials Summary. In Thousands, USD TTM 31-Dec-2024 FY 2024 … WebFind market predictions, CSL financials and market news. ... Market capitalization. 144.798B AUD. Dividends yield (FY) 1.13%. Price to earnings Ratio (TTM) 46.98. Basic …
WebFind the latest CSL Limited (CSL.AX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Market Cap: 146.587B: Beta (5Y … WebMarket Cap. AU$144.75bn. Enterprise Value. AU$163.97bn. Revenue. $10.56bn. ... and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus …
Webtransplant therapeutic areas. CSL Behring drives more than 85% of overall company revenue with substantial markets in Asia Pacific, Europe and North America. CSL Plasma, a division of CSL Behring, operates one of the world’s largest plasma collection networks, providing human plasma to CSL Behring for the manufacture and distribution of ... WebAug 19, 2024 · The Covid-19 pandemic has offered proof of concept for the promise of mRNA vaccines, and now CSL Behring's Seqirus unit wants to take the next step with technology it thinks will drive the field ...
WebCSL Limited delivered full-year net profit of $2.375 billion. Corporate Message 19 Aug 2024. CSL, the parent company of CSL Behring, delivered a strong full-year result, with reported net profit after tax of $2,375 million [1] , up 10% at CC [2] , reflecting. Critical operations maintained during COVID-19 pandemic, demonstrating CSL’s ...
WebCSL's 2024 Half Year Financial Results - Announcement Information. We have announced our 2024 Half Year Results for the period ending 31st December 2024. Announcement Information and Webcast Recording were released on Tuesday, 14th February 2024 (AEDT). Please click the 'Learn More' link for full information. Learn More. shrubs you don\\u0027t have to pruneWebFind market predictions, CSL financials and market news. ... Market capitalization. 144.798B AUD. Dividends yield (FY) 1.13%. Price to earnings Ratio (TTM) 46.98. Basic EPS (TTM) 6.51 AUD. About CSL … shrubs you don\u0027t have to pruneWebOur Products. CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries living with … shrubs you don\\u0027t have to trimWebMarket Cap $144.8B; Shares Outstanding 482.22M; Public Float 480.65M; Beta 0.90; Rev. per Employee $563.80K; ... It operates through the following segments: CSL Behring … shrubs you don\u0027t have to trimWebCSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in ... shrubs you can plant in fallWeb26 rows · Market Capitalization Definition. Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric … theory of change toolWebThe forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. theory of change statement